Human IFN-alpha 2/IFNA2 Antibody Summary
Met1-Glu188
Accession # P01563
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
IFN‑ alpha 2/IFNA2 Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN‑ alpha 2/IFNA2 Antibody. Recombinant Human IFN-alpha 2/IFNA2 reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IFN-alpha 2/IFNA2 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IFN-alpha 2/IFNA2 Monoclonal Antibody (Catalog # MAB93452). The ND50 is typically 0.6-3.6 ng/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IFN-alpha 2/IFNA2
Interferon-alpha 2 (IFNA2), also known as leukocyte interferon, is a type I interferon produced by macrophages, CD8 resting T cells, tonsillar NK cells, germinal center B cells, as well as epithelial cells, tumor cells and melanocytes. IFN alpha has at least nine different isoforms.
IFNA2 is a ligand for a cell surface receptor with two subunits, IFN-alpha R2 (ligand binding) and IFN-alpha R1 (ligand binding and signal transduction). IFNA2 has both antiviral and immunomodulatory activities on target cells. Intranasal administration has been shown to reduce viral load in subjects with the common cold. While IFNA2 is a prognostic factor for hepatocellular carcinoma, Interferon alpha 2b, has been used to treat melanoma, renal cell carcinoma, chronic myelogenous leukemia and hepatitis C.
- Chen, Zy et al. (2014) Br. J. Cancer 110:733.
- Burchert, A. et al. (2015) Leukemia 29:1331.
- Perrakis, A. et al. (2011) Transplant Proc. 43:3824.
- Akaza, H. et al. (2011) Jpn. J. Clin. Oncol. 41:1023.
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human IFN-alpha 2/IFNA2 Antibody
There are currently no reviews for this product. Be the first to review Human IFN-alpha 2/IFNA2 Antibody and earn rewards!
Have you used Human IFN-alpha 2/IFNA2 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image